A growing number of studies have proved the activation of the PI3K/AKT/mTOR pathway in EOC [35–38], although the Cancer Genome Atlas research detected a low mutational rate (< 5%) of PI3KCA, AKT and PTEN in high-grade serous ovarian carcinomas (HsOCs) [39]. This evidence concerns the gene MTOR and ovarian serous carcinoma.